Literature DB >> 29946183

Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.

Gregor Krings1, Yunn-Yi Chen2.   

Abstract

Metaplastic breast carcinomas comprise a histologically heterogenous group of tumors. Although most are triple (estrogen/progesterone receptor, HER2) negative, these rare tumors are clinicopathologically distinct from other triple negative carcinomas and may be aggressive with worse chemotherapy responses. On the other hand, metaplastic carcinomas are histologically diverse, which is reflected in gene expression differences among subtypes. Whether metaplastic carcinomas are genetically distinct from other triple negative cancers and whether genetic differences underlie histologic subtypes remains poorly understood. We sequenced 408 cancer-related genes in 28 metaplastic carcinomas, including chondroid matrix-producing carcinomas (n = 10), spindle cell carcinomas (n = 5), and carcinomas with squamous (n = 5), mixed spindle/squamous (n = 5), and mixed metaplastic (n = 3) differentiation. Metaplastic carcinomas were highly enriched for PIK3CA/PIK3R1 (61%) and Ras-Map kinase (25%) pathway aberrations compared to other triple negative carcinomas (TCGA dataset 14%, p < 0.001 and 7%, p = 0.005, respectively) and harbored a high frequency of TP53 (64%) and TERT promoter (25%) mutations, but this varied among subtypes. Chondroid-matrix producing carcinomas lacked PI-3 kinase and Ras-Map kinase aberrations and TERT promoter mutations, compared to 100%, 39%, and 39% of non-matrix-producing tumors, respectively. TERT promoter mutations were enriched (47%) in spindle cell carcinomas and tumors with squamous or spindle/squamous differentiation. Spindle cell carcinomas lacked TP53 mutations, in contrast to other subtypes (78%, p = 0.003). Separate analysis of paired ductal carcinoma in situ and metaplastic carcinoma revealed shared clonality in all cases (n = 8). Activating PI-3 kinase and Ras pathway mutations were early events, and inactivating mutations in tumor suppressors including RB1, CDKN2A, and TP53 were associated with invasion in individual cases. Metaplastic components of two tumors showed genetic progression from separately sequenced paired invasive ductal carcinoma. The findings suggest that metaplastic carcinomas are genetically distinct from other triple negative breast cancers and highlight genetic heterogeneity that broadly correlates with histologic subtype. Heterologous elements progress from associated ductal carcinoma.

Entities:  

Mesh:

Year:  2018        PMID: 29946183     DOI: 10.1038/s41379-018-0081-z

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

1.  ASO Author Reflections: Metaplastic Breast Cancer-The Case for Doing Less and More.

Authors:  Oluwadamilola M Fayanju
Journal:  Ann Surg Oncol       Date:  2018-11-09       Impact factor: 5.344

2.  Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation.

Authors:  Francisco Beca; Ana P M Sebastiao; Fresia Pareja; Kimberly Dessources; John R Lozada; Felipe Geyer; Pier Selenica; Nebras Zeizafoun; Hannah Y Wen; Larry Norton; Edi Brogi; Britta Weigelt; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2020-08       Impact factor: 5.087

Review 3.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

Review 4.  Rare Breast Cancer Subtypes.

Authors:  Sarah Jenkins; Megan E Kachur; Kamil Rechache; Justin M Wells; Stanley Lipkowitz
Journal:  Curr Oncol Rep       Date:  2021-03-23       Impact factor: 5.075

5.  Clinicopathologic and genetic features of metaplastic breast cancer with osseous differentiation: a series of 6 cases.

Authors:  Xue Chao; Wanlin Tan; Julia Y Tsang; Gary M Tse; Jintao Hu; Ping Li; Jinghui Hou; Mei Li; Jiehua He; Peng Sun
Journal:  Breast Cancer       Date:  2021-05-03       Impact factor: 4.239

6.  Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.

Authors:  Jasmine A McQuerry; David F Jenkins; Susan E Yost; Yuqing Zhang; Daniel Schmolze; W Evan Johnson; Yuan Yuan; Andrea H Bild
Journal:  BMC Cancer       Date:  2019-09-05       Impact factor: 4.430

7.  Fibromatosis-like metaplastic carcinoma: a case report and review of the literature.

Authors:  Jasper Victoor; Claire Bourgain; Sara Vander Borght; Isabelle Vanden Bempt; Carine De Rop; Giuseppe Floris
Journal:  Diagn Pathol       Date:  2020-03-03       Impact factor: 2.644

8.  Case Reports on Metaplastic Squamous Cell Carcinoma of the Breast and Treatment Dilemma.

Authors:  Anita Pandey; Kishor Joshi; Harry Moussouris; Gardith Joseph
Journal:  Case Rep Oncol Med       Date:  2019-09-18

9.  Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.

Authors:  F Coussy; R El Botty; M Lavigne; C Gu; L Fuhrmann; A Briaux; L de Koning; A Dahmani; E Montaudon; L Morisset; L Huguet; L Sourd; P Painsec; S Chateau-Joubert; T Larcher; S Vacher; S Melaabi; A Vincent Salomon; E Marangoni; I Bieche
Journal:  J Hematol Oncol       Date:  2020-02-22       Impact factor: 17.388

Review 10.  A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.

Authors:  Tejaswini P Reddy; Roberto R Rosato; Xiaoxian Li; Stacy Moulder; Helen Piwnica-Worms; Jenny C Chang
Journal:  Breast Cancer Res       Date:  2020-11-04       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.